Development of new generation of Tc-99m kits

IAEA continues to harness the CRP mechanism as a major platform for coordination of research and development activities on the production and quality control of radiopharmaceuticals and their application for non-communicable human diseases. This is an important part of the IAEA's remit to generate amd distribute knowledge involving atoms for peace for all Member States.  In order to best optimise production and sustainable application of Tc-99m and related kits worldwide as well as define future activities to enhance and develop production capacities in Mmber States, the IAEA has recently held a number of meetings and networking activties on the subject . From those meetings, a major recommendation was put forward to plan and initiate an IAEA CRP for 2024-2028 on the development of novel target kits and molecules, and  enhance their impact by strengthening mechanisms of knowledge transfer of the related radiopharmaceuticals (small molecules, peptides, antibodies, etc.), preclinical studies and health regulatory issues, etc. As an outcome of the CRP, the IAEA Member States should adopt the developed kit/molecule production and preclinical evaluation of selected Tc-99m radiopharmaceuticals with IAEA's assistance through published guidelines. Many IAEA Member States are potential users of these materials and would benefit from such a publication/guideline.